_256_384.jpg)
Drug Approval | April 07, 2024
Cipla Patalganga facility gets 6 USFDA observations
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The company plans to add 1700 beds by FY27 through the organic route
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The average time of dilation lasts three to eight hours
Application based on results from the TROPION-Breast01 Phase III trial
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
This acquisition enables MTD to open new, strategic markets
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Subscribe To Our Newsletter & Stay Updated
